Earnings Call · Q2 FY2022·2022-08-15

Q2 22EPS -26.92%·Rev n/aQ1 22EPS +4.33%·Rev n/aQ4 21EPS +34.62%·Rev n/aQ3 21EPS -100.00%*·Rev n/a⚠ consensus missing

GeneDx Holdings Corp. WGS

Joel Kaufman — VP of Finance and Corporate Development

Katherine Stueland — Chief Executive Officer

Kevin Feeley — SVP of Operations and Head of GeneDx

−33.3%1d on move date−33.5% vs SPY3d−46.3%5d−52.5%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more WGS calls or request research access.

More WGS calls Browse calls Request research access